Protecting health care workers from tuberculosis, 2013: ACOEM Medical center occupational health section task force on tuberculosis and health care workers

Journal of Occupational and Environmental Medicine

Volumn 55, Issue 8, 2013, Pages 985-988

  Behrman, Amy ^a   Buchta, William G ^a   Budnick, Lawrence D ^a   Hodgson, Michael J ^a   Raymond, Lawrence W ^a   Russi, Mark ^a   Spillmann, Scott J ^a   Swift, Melanie D ^a  

^a ACOEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; IMMUNOSUPPRESSIVE AGENT; ISONIAZID; QUINOLONE DERIVATIVE; RIFAMPICIN; RIFAPENTINE;

ARTICLE; BACTERIAL STRAIN; BACTERIUM DETECTION; BCG VACCINATION; DISEASE COURSE; DISEASE SURVEILLANCE; DRUG RESISTANT TUBERCULOSIS; ENVIRONMENTAL HEALTH; EPIDEMIOLOGY; HEALTH CARE FACILITY; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HEALTH PROMOTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; LUNG TUBERCULOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM MARINUM; OCCUPATIONAL HEALTH; OCCUPATIONAL PHYSICIAN; PREVALENCE; PUBLIC HEALTH; RISK ASSESSMENT; RISK REDUCTION; THORAX RADIOGRAPHY; TREATMENT DURATION;

HEALTH PERSONNEL; HUMANS; OCCUPATIONAL DISEASES; OCCUPATIONAL HEALTH; RISK FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84883402906     PISSN: 10762752     EISSN: 15365948     Source Type: Journal    
DOI: 10.1097/JOM.0b013e3182a0d7cd     Document Type: Article

References (34)

1. Centers for Disease Control and Prevention. Fact sheet: trends in tuberculosis, 2011. Available at: www.cdc.gov/tb/publications/factsheets/ statistics/TBTrends.htm. Accessed March 12, 2013.
2. Russi M, Buchta W, Swift M, et al. Guidance for Occupational Health Services in Medical Center. Elk Grove, Ill: American College of Occupational and Environmental Medicine; 2008. Available at: http://www.acoem.org/uploadedFiles/ Public-AffairsPolicies-And-Position-Statements/Guidelines/Guidelines/ MCOH%20Guidance.pdf. Accessed July 1, 2013.
3. Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in healthcare settings, 2005. Morb Mortal Wkly Rep. 2005;54:1-141. Available at: www.cdc.gov/mmwr/PDF/rr/rr5417. pdf. Accessed March 13, 2013.
4. Centers for Disease Control and Prevention. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis-United States, 2010. MMWR. 2010;59:1-25. Available at: www.cdc.gov/mmwr/preview/ mmwrhtml/rr5905a1.htm. Accessed March 13, 2013.
5. Nicas M. Respiratory protection and the risk of Mycobacterium tuberculosis infection. Am J Ind Med. 1995;27:317-333.
6. Lee K, Slavcev A, Nicas M. Respiratory protection against Mycobacterium tuberculosis: quantitative fit test outcomes for five type N95 filtering-facepiece respirators. J Occup Environ Hyg. 2004;1:22-28.
7. Coffey CC, Lawrence RB, Campbell DL, Zhuang Z, Calvert CA, Jensen PA. Fitting characteristics of eighteen N95 filteringfacepiece respirators. J Occup Environ Hyg. 2004;1:262-271.
8. Occupational Safety and Health Administration. Respiratory Protection Standard (1910.134). Available at: www.osha.gov/pls/oshaweb/owadisp.show document?p table=STANDARDS&p id=12716. Accessed March 13, 2013.
9. Daniel TM. The history of tuberculosis. Respir Med. 2006;100:1862-1870.
10. Khoury NZ, Binnicker MJ, Wengenack NL, Aksamit TR, Buchta WG, Molella RG. Preemployment screening for tuberculosis in a large health care setting: comparison of the tuberculin skin test and a whole-blood interferongamma release assay. J Occup Environ Med. 2011;53:290-293.
11. American Lung Association. The American Lung Association Conference on reestablishing control of tuberculosis in the United States. Am J Respir Crit Care Med. 1996;154:251-262.
12. McKenna MT, McCray E, Onorato I. The epidemiology of tuberculosis among foreignborn persons in the United States, 1986 to 1993. N Engl J Med. 1995;332:1071-1076. Available at: www.nejm.org/doi/full/10.1056/ NEJM199504203321606#t=articleTop. Accessed March 12, 2013.
13. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med. 1992;326:231-235. Available at: www.nejm.org/doi/full/10.1056/ NEJM199201233260404. Accessed March 12, 2013.
14. Menzies D, Fanning A, Yuan L, Fitzgerald M. Tuberculosis among health care workers. N Engl J Med. 1995;332:92-98.
15. Bowden KM, McDiarmid MA. Occupationally acquired tuberculosis: what's known. J Occup Med. 1994;36:320-325.
16. Dooley SW, Villarino ME, Lawrence M, et al. Nosocomial transmission of tuberculosis in a hospital unit for HIVinfected patients. JAMA. 1992;267:2632-2634.
17. Beck-Sagúe C, Dooley SW, HuttonMD, et al. Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients. JAMA. 1992;268:1280-1286.
18. Kenyon TA, Ridzon R, Luskin-Hawk R, et al. A nosocomial outbreak of multidrug-resistant tuberculosis. Ann Intern Med. 1997;127: 32-6.
19. Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 2011. Atlanta, GA: US Department of Health and Human Services; October 2012. Available at: www.cdc.gov/tb/statistics/reports/2011/pdf/ report2011.pdf. Accessed March 13, 2013.
20. Horsburgh CR, Rubin EJ. Latent tuberculosis infection in the United States. N Engl J Med. 2011;364:1441-1448. Available at: www.casemedicine.com/ ambulatory/Continuity %20Clinic/Clinic%20Articles/3)%20September/1) Week%20of%20Sepember%205th/LTI.nejm. pdf. Accessed March 12, 2013.
21. Lambert L, Rajbhandary S, Qualls N, et al. Costs of implementing and maintaining a tuberculin skin test program in hospitals and health departments. Infect Control Hosp Epidemiol. 2003;24:814-820.
22. Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: a costeffective analysis. Int J Tuberc Lung Dis. 2007;11:16-26.
23. Wrighton-Smith P, Sneed L, Humphrey F, Tao X, Bernacki E. Screening health care workers with interferon-? release assay versus tuberculin skin test: impact on costs and adherence to testing (the SWITCH study). J Occup Environ Med. 2012;54:806-815.
24. Ringshausen FC, Schablon A, Nienhaus A. Interferon-gamma release assays for the tuberculosis serial testing of health care workers: a systematic review. J Occup Med Toxicol. 2012;7:6. Available at: www.ncbi. nlm.nih.gov/pmc/ articles/PMC3377540/. Accessed March 12, 2013.
25. Fong KS, Tomford JW, Teixeira L, et al. Challenges of interferon-? release assays in serial testing of health-care workers in a tuberculosis control program. Chest. 2012;142:55-62.
26. Thanassi W, Noda A, Hernandez B, et al. Delineating a retesting zone using receiver operating characteristic analysis on serial QuantiFERON tuberculosis test results in US healthcare workers. Pulm Med. 2012. Available at: www.ncbi.nlm.nih.gov/pmc/articles/PMC3544373/. Accessed March 12, 2013.
27. Vinnard C, Linkin D, Behrman A. Current approach to latent tuberculosis diagnosis and treatment among medical center occupational health physicians. Infect Control Hosp Epidemiol. 2012;33:1262-1265.
28. Canadian Tuberculosis Committee. Recommendations on interferon gamma release assays for the diagnosis of latent tuberculosis infection-2010 update. An Advisory Committee Statement. Can Commun Dis Rep. 2010;36:1-22. Available at: www.phac-aspc.gc.ca/publicat/ccdr-rmtc/10pdf/36-acs-5.pdf . Accessed March 13, 2013.
29. McGill University. Online TST/IGRA Interpreter. Available at: www.tstin3d.com/en/calc. html. Accessed March 13, 2013.
30. Centers for Disease Control and Prevention. Treatment of tuberculosis, 2003. Morb Mortal Wkly Rep. 2003;52;1-77. Available at: www.cdc.gov/mmwr/ preview/mmwrhtml/rr5211a1.htm. Accessed March 13, 2013.
31. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med. 2005;172:1169-1227. Available at: http://ajrccm.atsjournals.org/content/172/9/1169.full.pdfhtml. Accessed March 13, 2013.
32. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest. 2006;130:1712-1717. Available at: http://journal.publications.chestnet.org/article .aspx?articleid=1084861. Accessed March 13, 2013.
33. Sterling TR, Villarino ME, Borisov AS, et al; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155-2166. Available at: www.nejm.org/doi/pdf/10.1056/NEJMoa1104875. Accessed March 13, 2013.
34. Centers for Disease Control and Prevention. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. Morb Mortal Wkly Rep. 2011;60;1650-1653. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm. Accessed March 13, 2013.